(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.38%) $0.929
(-1.10%) $10.87
(-0.12%) $0.797
(0.52%) $91.61
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.33%
Live Chart Being Loaded With Signals
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders...
Stats | |
---|---|
今日成交量 | 259 837 |
平均成交量 | 330 240 |
市值 | 172.32M |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $-0.110 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.59 |
ATR14 | $0.0130 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-23 | Collier Earl M Jr | Buy | 30 000 | Common Stock |
2024-04-23 | Collier Earl M Jr | Sell | 30 000 | Stock Option (Right to Buy) |
2024-04-23 | Musket David B | Buy | 16 156 | Common Stock |
2024-04-23 | Musket David B | Sell | 5 750 | Stock Option (Right to Buy) |
2024-01-02 | Kelliher Mike | Buy | 30 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
79.04 |
Last 97 transactions |
Buy: 2 824 525 | Sell: 392 146 |
音量 相关性
Capricor Therapeutics Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Capricor Therapeutics Inc 相关性 - 货币/商品
Capricor Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $25.18M |
毛利润: | $24.11M (95.75 %) |
EPS: | $-0.830 |
FY | 2023 |
营收: | $25.18M |
毛利润: | $24.11M (95.75 %) |
EPS: | $-0.830 |
FY | 2022 |
营收: | $2.55M |
毛利润: | $1.85M (72.74 %) |
EPS: | $-1.180 |
FY | 2021 |
营收: | $245.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.000867 |
Financial Reports:
No articles found.
Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。